1. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified
by Maja Ludvigsen, Martin Bjerregård Pedersen, Kristina Lystlund Lauridsen, Tim Svenstrup Poulsen, Stephen Jacques Hamilton-Dutoit, Søren Besenbacher, Knud Bendix, Michael Boe Møller, Peter Nørgaard, Francesco d’Amore, and Bent Honoré
BloodAdv
Volume 2(19):
October 9, 2018
© 2018 by The American Society of Hematology

2. Maja Ludvigsen et al. Blood Adv 2018;2:2533-2542
© 2018 by The American Society of Hematology

3. Study design and flowchart of the analyses.
Study design and flowchart of the analyses. Initially proteins in all samples were separated using 2D-PAGE. PTCL-NOS cases were dichotomized according to PCA and clinical outcome in C1 vs C2 and G1 vs G2, respectively. Differential protein expressions were compared in: analysis A, PTCL-NOS (n = 18) vs N (n = 8); analysis B, PCA defined clusters C1 (n = 7) vs C2 (n = 11); and analysis C, PTCL-NOS patients with primary refractory disease (G1) with survival <100 days (n = 4) vs PTCL-NOS patients with chemosensitive disease and survival >2 years (G2) (n = 8). In the latter analysis, 6 cases were omitted for failing to fulfill the defined criteria of treatment response. Spots with ≥twofold differential expression were excised, and protein identifications were performed by liquid chromatography tandem mass spectrometry (LC-MS/MS). ENO1, TPI1, and ALDH2 protein expression was assessed in a larger cohort of PTCL-NOS patients (n = 87) by IHC and digitally quantified using digital image analysis on TMA cores. ALDH2, aldehyde dehydrogenase 2, mitochondrial; CR, complete remission; N, nonneoplastic tissue; TPI1, triosephosphate isomerase.
Maja Ludvigsen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. PCA cluster analysis.
PCA cluster analysis. (A) PCA analysis showing distinct separation of PTCL-NOS tumors from nonneoplastic lymphoid reference tissue and additional clustering within PTCL-NOS in distinct groups (ie, C1 and C2). (B) Hierachical clustering showing distinct protein profiles between N, C1, and C2. With this analysis, 1 of the C2 patients clustered with the C1 group. Green denotes downregulation, and red denotes upregulation. (C) OS of PTCL-NOS patients according to groups (C1 and C2) identified from cluster analysis. N, nonneoplastic lymphoid tissue.
Maja Ludvigsen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Immunohistochemical evaluation of putative predictive markers and outcome in PTCL-NOS patients.
Immunohistochemical evaluation of putative predictive markers and outcome in PTCL-NOS patients. Representative images showing high and low expression of ENO1 (A-B), ALDH2 (D-E), and TPI1 (G-H) by IHC are shown in PTCL-NOS tissue. OS curves for the patients according to marker expression (C,F,I).Original magnification ×10.
Maja Ludvigsen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology